- Home
- WDC vs ABBV Comparison
WDC vs ABBV Comparison
Compare WDC & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WDC | ABBV |
|---|---|---|
| Founded | 1970 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.4B | 358.5B |
| IPO Year | 1999 | 2012 |
Fundamental Metrics
Financial Performance| Metric | WDC | ABBV |
|---|---|---|
| Price | $778.61 | $221.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 18 |
| Target Price | ★ $281.77 | $253.71 |
| AVG Volume (30 Days) | ★ 6.0M | 3.4M |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | 0.12% | ★ 3.39% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 16.05 | 0.39 |
| Revenue | $9,520,000,000.00 | ★ $61,160,000,000.00 |
| Revenue This Year | $32.24 | $11.87 |
| Revenue Next Year | $26.55 | $8.12 |
| P/E Ratio | ★ $44.38 | $566.36 |
| Revenue Growth | N/A | ★ 8.57 |
| 52 Week Low | $58.97 | $181.75 |
| 52 Week High | $741.85 | $244.81 |
Technical Indicators
Market Signals| Indicator | WDC | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 76.32 | 54.35 |
| Support Level | $457.44 | $220.11 |
| Resistance Level | N/A | $230.91 |
| Average True Range (ATR) | 38.89 | 5.07 |
| MACD | 13.82 | -0.22 |
| Stochastic Oscillator | 91.07 | 56.89 |
Price Performance
Historical ComparisonAbout WDC Western Digital Corporation
Western Digital is a leading vertically integrated supplier of hard disk drives. The HDD market is a practical duopoly, with Western Digital and Seagate being the two largest players. Western Digital designs and manufactures its HDDs, with much of the manufacturing and workforce located in Asia. The primary consumers of HDDs are data centers.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.